Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03411837 · ClinicalTrials.gov registry record
Dupilumab Phase 4 Study
A clinical trial, sponsored by Northwestern University.
- Terminated
- Registry status
- 46
- Enrollment target
NCT03411837: Clinical Trial study, sponsored by Northwestern University.
NCT03411837 is a clinical trial that was terminated before completion, run by Northwestern University. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03411837 was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- 46 participants
- Enrollment target
Study Summary
The investigators will monitor for the incidence of adverse-events in a prospective, longitudinal, non-interventional and observational real-world sub-study of adults patients with moderate-to-severe AD who are receiving dupilumab as standard-of-care therapy.
Interventions
- BIOLOGICAL Dupilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2019-08-31 |
Why NCT03411837 stopped before completion
NCT03411837 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 46 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Dupilumab is the first listed.
NCT03411837 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03411837 about?
NCT03411837 is a clinical study titled "Dupilumab Phase 4 Study". The investigators will monitor for the incidence of adverse-events in a prospective, longitudinal, non-interventional and observational real-world sub-study of adults patients with moderate-to-severe AD who are receiving dupilumab as standard-of-care therapy.
What is the current status of trial NCT03411837?
This trial is currently terminated. The enrollment target is 46 participants. The study started on 2017-10-16. Estimated completion is 2019-08-31.
What interventions are being tested in trial NCT03411837?
The interventions under investigation include: Dupilumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03411837?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI